Search For "subject expert committee"
COVID-19 vaccination for children: CDSCO approved ZyCoV-D for rest
Updated : 2 days, 17 hours ago IST
New Delhi [India], November 30 (ANI): The Interim Phase II, III clinical trial data of COVAXIN on Healthy Volunteers aged 2 to 18 years submitted by Bharat Biotech was deliberated in the meeting of the Subject Expert Committee (SEC) on August 28 and October 11, informed Ministry of Health an
Read More
Covaxin for 2-18 yrs: Centre examining Expert Committee recommenda
Updated : 2 days, 20 hours ago IST
New Delhi [India], November 30 (ANI): The Central government is examining the recommendation of the Subject Expert Committee (SEC) regarding the grant of market authorization of Covaxin for the age group of 2 to 18 years for restricted use in an emergency situation subject to various cond
Read More
Awaiting regulatory approval for rolling out Covaxin for children
Updated : 1 month, 3 weeks ago IST
New Delhi [India], October 12 (ANI): The Subject Expert Committee (SEC) has given a recommendation to the Drugs Controller General of India (DCGI) for the use of Bharat Biotech's COVID-19 vaccine, Covaxin, for the beneficiaries aged between 2-18 years, the official sources said on Tuesday
Read More
COVID-19: Subject Expert Committee gave recommendation to DCGI to
Updated : 1 month, 3 weeks ago IST
New Delhi [India], October 12 (ANI): Subject Expert Committee (SEC) has given a recommendation to the Drugs Controller General of India (DCGI) for the use of Bharat Biotech's COVID-19 vaccine Covaxin for the beneficiaries aged between 2-18 years, the official sources said.
Read More
Sputnik Light Covid vaccine gets permission for Phase 3 trials in
Updated : 2 months, 2 weeks ago IST
New Delhi [India], September 15 (ANI): The Drug Controller General of India has given its approval to the single-dose COVID-19 vaccine version of the Sputnik V vaccine 'Sputnik Light' to conduct trials on the Indian population to check whether the vaccine gives a similar immune response i
Read More
SEC recommends Phase 1 clinical trials of Reliance's Covid Vaccine
Updated : 3 months, 1 week ago IST
New Delhi [India], August 27 (ANI): The Subject Expert Committee (SEC) has recommended Phase 1 clinical trials of Reliance's recombinant COVID-19 vaccine candidate.
Read More
Expert panel recommends trials on mixing Covaxin and Covishield
Updated : 4 months ago IST
New Delhi [India], July 30 (ANI): The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Thursday recommended granting permission for trials of mixing COVID-19 vaccines--Covaxin and Covishield--said sources.
Read More
Zydus Cadila expected to provide additional data on Covid-19 vacci
Updated : 4 months, 2 weeks ago IST
New Delhi [India], July 20 (ANI): Emergency approval for Zydus Cadila's Covid-19 vaccine may take a few more days with the Ahmedabad-based pharma company set to submit additional data related to immunogenicity and safety of its Zycov-D vaccine to the Drugs Controller General of India (DCGI)
Read More
Dr Reddy's denied approval for Phase 3 trials of Sputnik Light Cov
Updated : 5 months ago IST
New Delhi [India], July 1 (ANI): The central government's Subject Expert Committee (SEC) has denied permission to Dr Reddy's Laboratories for conducting Phase 3 trials of Russia's COVID-19 vaccine Sputnik Light in India.
Read More
Bharat Biotech's Covaxin shows 77.8 pc efficacy in Phase III trial
Updated : 5 months, 1 week ago IST
New Delhi [India], June 22 (ANI): Bharat Biotech's Covaxin has shown 77.8 per cent efficacy after the Subject Expert Committee (SEC) under the drug regulator reviewed its Phase III trials data on Tuesday, according to sources.
Read More
DCGI's expert panel to review Phase III data of Covaxin today
Updated : 5 months, 2 weeks ago IST
New Delhi [India], June 22 (ANI): The Subject Expert Committee (SEC) under the drug regulator will discuss reviewing the Phase III data of Bharat Biotech's Covaxin on Tuesday.
Read More
Zydus Cadila, first Indian Company gets recommendation for clinica
Updated : 6 months ago IST
New Delhi [India], June 4 (ANI): The only Indian company Zydus Cadila which claims to have developed neutralising monoclonal antibodies (mAbs)-based cocktail for the treatment of COVID-19 has been recommended to conduct clinical trials by the Subject Expert Committee (SEC) of Central Drug
Read More